Study of CT1194C for relapsed B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new therapy called CT1194C for people with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. It aims to see if the therapy is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of B-cell lymphoma that has come back or not responded to treatment.
- You are between 18 and 75 years old.
- You have already had at least two different types of treatment for your lymphoma.
- You have a tumor that can be seen on scans and you are well enough to be active (ECOG 0 or 1).
- You are willing to use effective birth control for one year after treatment and not donate sperm or eggs during that time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This trial is testing an investigational cell therapy called CT1195E for people with certain types of B-cell lymphoma or acute lymphoblastic leukemia that has come back or stopped responding to treatment. The goal is to see if CT1195E can help control the cancer.
This clinical trial tests a new cell therapy, CT1194D, for people whose B-cell lymphoma (a type of blood cancer) or B-cell acute lymphoblastic leukemia has come back or is not responding to standard treatments. The goal is to see if this therapy can help shrink tumors or improve blood cell counts.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.